HU229320B1 - Phospholipid derivatives of valproic acid and mixtures thereof - Google Patents

Phospholipid derivatives of valproic acid and mixtures thereof Download PDF

Info

Publication number
HU229320B1
HU229320B1 HU0302635A HUP0302635A HU229320B1 HU 229320 B1 HU229320 B1 HU 229320B1 HU 0302635 A HU0302635 A HU 0302635A HU P0302635 A HUP0302635 A HU P0302635A HU 229320 B1 HU229320 B1 HU 229320B1
Authority
HU
Hungary
Prior art keywords
vpa
vfa
pharmaceutical composition
administration
nervous system
Prior art date
Application number
HU0302635A
Other languages
English (en)
Hungarian (hu)
Inventor
Alexander Kozak
Original Assignee
Dpharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dpharm Ltd filed Critical Dpharm Ltd
Publication of HUP0302635A2 publication Critical patent/HUP0302635A2/hu
Publication of HUP0302635A3 publication Critical patent/HUP0302635A3/hu
Publication of HU229320B1 publication Critical patent/HU229320B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU0302635A 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof HU229320B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
PCT/IL2001/000629 WO2002007669A2 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Publications (3)

Publication Number Publication Date
HUP0302635A2 HUP0302635A2 (hu) 2003-11-28
HUP0302635A3 HUP0302635A3 (en) 2007-06-28
HU229320B1 true HU229320B1 (en) 2013-10-28

Family

ID=24460534

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302635A HU229320B1 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Country Status (20)

Country Link
US (2) US6313106B1 (enExample)
EP (1) EP1315506B1 (enExample)
JP (1) JP5140224B2 (enExample)
KR (1) KR100801213B1 (enExample)
CN (1) CN100536851C (enExample)
AT (1) ATE461697T1 (enExample)
AU (2) AU2001270962B8 (enExample)
BR (1) BR0112337A (enExample)
CA (1) CA2415354C (enExample)
CY (1) CY1110113T1 (enExample)
CZ (1) CZ305745B6 (enExample)
DE (1) DE60141636D1 (enExample)
DK (1) DK1315506T3 (enExample)
ES (1) ES2343403T3 (enExample)
HU (1) HU229320B1 (enExample)
IL (1) IL153147A0 (enExample)
MX (1) MXPA03000326A (enExample)
NZ (1) NZ522788A (enExample)
PT (1) PT1315506E (enExample)
WO (1) WO2002007669A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
AU2003217791A1 (en) 2002-02-28 2003-09-16 A And D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
EP1928807A4 (en) * 2005-09-02 2011-05-04 Picobella Llc ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
AU2013257710B2 (en) * 2012-05-08 2016-10-20 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
JP3019994B2 (ja) 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
WO1990010448A2 (en) 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (enExample) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Also Published As

Publication number Publication date
WO2002007669A2 (en) 2002-01-31
IL153147A0 (en) 2003-06-24
EP1315506A2 (en) 2003-06-04
ATE461697T1 (de) 2010-04-15
WO2002007669A3 (en) 2003-01-09
CN100536851C (zh) 2009-09-09
AU7096201A (en) 2002-02-05
KR100801213B1 (ko) 2008-02-05
US20040033987A1 (en) 2004-02-19
CY1110113T1 (el) 2015-01-14
BR0112337A (pt) 2004-06-08
CA2415354C (en) 2009-09-29
EP1315506A4 (en) 2005-03-30
KR20030034099A (ko) 2003-05-01
AU2001270962B2 (en) 2006-03-16
HUP0302635A3 (en) 2007-06-28
DE60141636D1 (de) 2010-05-06
CN1774252A (zh) 2006-05-17
JP5140224B2 (ja) 2013-02-06
CZ305745B6 (cs) 2016-03-02
HUP0302635A2 (hu) 2003-11-28
CZ200386A3 (cs) 2003-06-18
JP2004509854A (ja) 2004-04-02
AU2001270962B8 (en) 2006-08-10
CA2415354A1 (en) 2002-01-31
DK1315506T3 (da) 2010-05-31
EP1315506B1 (en) 2010-03-24
US6313106B1 (en) 2001-11-06
NZ522788A (en) 2005-04-29
PT1315506E (pt) 2010-05-17
ES2343403T3 (es) 2010-07-30
MXPA03000326A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
Fatehi et al. Effects of Crocus sativus petals’ extract on rat blood pressure and on responses induced by electrical field stimulation in the rat isolated vas deferens and guinea-pig ileum
CN105025900B (zh) 包含5型磷酸二酯酶抑制剂的神经细胞的细胞凋亡抑制用组合物
HU228847B1 (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
CN105147757A (zh) 包含菊花提取物的组合物以及其用在皮肤美白和皮肤提亮应用中的方法
FR2482093A1 (fr) Nouveaux derives d'ocytocine et compositions pharmaceutiques contenant ces derives
ES2251097T3 (es) Tratamiento con cromo/biotina de la diabetes tipo ii.
CA2927499A1 (en) Skin care compositions and methods of use thereof
JP2005535608A5 (enExample)
KR101705338B1 (ko) 항산화, 항노화 및 자가포식 활성을 가지는 조성물 및 이의 용도
ES2471190T3 (es) Composiciones farmacéuticas que comprenden compuestos de tipo cannabicromeno
ES2140392T5 (es) Metodo y composicion para mejorar los efectos adversos del envejecimiento.
FR2941150A1 (fr) Produit pour la prevention ou le traitement du blanchissement des cheveux.
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
FR2556216A1 (fr) Nouveau medicament analgesique contenant du proglumide, eventuellement en association avec des medicaments analgesiques-narcotiques
DeWys et al. Synergistic antileukemic effect of theophylline and 1, 3-bis (2-chloroethyl)-1-nitrosourea
JP2003137786A (ja) 発癌抑制効能を有するテオブロミン
EP1768684B1 (fr) Composition comprenant un extrait de lotus bleu pour le traitement des contractions musculaires faciales incontrôlees
KR20240070841A (ko) 톱니모자반으로부터 분리된 플라스토퀴논 나노에멀젼을 포함하는 치주염 예방 또는 치료용 약학 조성물
KR101578849B1 (ko) 진세노사이드 C-Mx1을 포함하는 두피 및 모근 강화를 통한 모발 성장 촉진용 샴푸 및 컨디셔너 조성물
KR101618349B1 (ko) 디하이드로안드로그라폴라이드를 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물
Kim et al. Indeno [1, 2-c] isoquinolines as enhancing agents on all-trans retinoic acid-mediated differentiation of human myeloid leukemia cells
KR101569773B1 (ko) 아르테메터를 포함하는 모발 성장 촉진용 화장료 또는 약학 조성물
KR20150082105A (ko) 5탄당 및 자일리톨을 유효성분으로 포함하는 구강 세균 부착 억제용 조성물
CN119950503A (zh) 生物活性植物化学物
JP6607676B2 (ja) Ｔｒｐｖ４活性化剤

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees